News

DOR BioPharma has entered into common stock purchase agreements with institutional investors totaling approximately $3.85m. DOR’s North American commercial partner, Sigma-Tau Pharmaceuticals, participated in this financing. Under the

Paladin Labs has received approval from the Biologics and Genetic Therapies Directorate of Health Canada for GlucaGen (recombinant glucagon for injection). GlucaGen is indicated for the treatment of

LEO Pharma is re-acquiring Warner Chilcott’s exclusive product licensing rights in the US to its topical psoriasis treatments Taclonex, Taclonex Scalp, Dovonex as well as rights to all

SuiteMed Solutions is customising their SuiteMed EHR to facilitate receipt of patient data from ALR Technologies’ patented Health-E-Connect patient monitoring system. SuiteMed Solutions’ EHR package will also include

Sanofi Pasteur has approved the results of the collaborative HIV vaccine trial that has been conducted in Thailand over the past six years. The phase III clinical trial

Amgen has announced detailed results from the phase 3 ‘203’ trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic

Lundbeck’s partner Teva has announced that results from the ADAGIO trial, which demonstrated that Parkinson’s disease patients receiving Azilect (rasagiline) 1mg/day at the start of the study (early-start

Sartorius Stedim Biotech will launch the commercially available membrane adsorber for hydrophobic interaction chromatography (HIC). Sartobind Phenyl membrane adsorbers allow increased flow rates to ensure faster processes and

HRA Pharma has entered into an exclusive agreement with the Australian drug delivery company Acrux to market and distribute Acrux’s transdermal estradiol spray in France, Germany, the UK,